A Vibrio-susceptibility class of antimicrobial peptide Ajapocin via membranolytic pattern to combat “non-cholera” pathogens in vivo infection models

Key Points

• Ajapocin effectively reduces non-cholera pathogen infections, showcasing its potent antimicrobial action.
• A significant reduction in pathogen load was observed across multiple in vivo models, showing promise for future applications.
• Assessment using various in vivo infection models demonstrates ajapocin's membranolytic activity against V. cholerae.
• This highlights the potential for new antimicrobial strategies using ajapocin in treating resistant infections.